Design and methods of the Population Assessment of Tobacco and Health (PATH) Study
Design and methods of the Population Assessment of Tobacco and Health (PATH) Study
复制标题
DOI：
10.1136/tobaccocontrol-2016-052934
复制
发表时间：
2017-07-01
期刊：
影响因子：
5.2
通讯作者：
Compton, Wilson M.
中科院分区：
文献类型：
--
作者：
Hyland, Andrew;Ambrose, Bridget K.;Compton, Wilson M.
背景本文介绍了烟草与健康人口评估（PATH）研究第一波数据收集的方法和概念框架。美国国立卫生研究院，通过国家药物滥用研究所，是与美国食品和药物管理局（FDA）的烟草制品中心合作进行的PATH研究根据合同与Westat.Methods的PATH研究是一个具有全国代表性的，纵向队列研究的45 971成人和青少年在美国，年龄在12岁及以上。第一波于2013年9月12日至2014年12月15日进行，使用音频计算机辅助自我访谈收集有关烟草使用模式、对当前和新出现的烟草产品的风险认知和态度、烟草开始、戒烟、复吸行为和健康结果的信息。PATH研究的设计允许对一系列烟草产品的使用模式进行纵向评估，包括开始、停止、复吸和产品之间的转换，以及与使用模式相关的因素。此外，PATH研究收集了18岁及以上成年人的生物样本，并测量了与烟草使用相关的暴露和潜在危害的生物标志物。PATH研究随时间推移生成的基于人群的数据将有助于为FDA在《家庭吸烟预防和烟草控制法》下的监管使命以及减少国家烟草负担的努力提供证据基础-相关的死亡和疾病。
Background This paper describes the methods and conceptual framework for Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study data collection. The National Institutes of Health, through the National Institute on Drug Abuse, is partnering with the Food and Drug Administration's (FDA) Center for Tobacco Products to conduct the PATH Study under a contract with Westat.Methods The PATH Study is a nationally representative, longitudinal cohort study of 45 971 adults and youth in the USA, aged 12 years and older. Wave 1 was conducted from 12 September 2013 to 15 December 2014 using Audio Computer-Assisted Self-Interviewing to collect information on tobacco-use patterns, risk perceptions and attitudes towards current and newly emerging tobacco products, tobacco initiation, cessation, relapse behaviours and health outcomes. The PATH Study's design allows for the longitudinal assessment of patterns of use of a spectrum of tobacco products, including initiation, cessation, relapse and transitions between products, as well as factors associated with use patterns. Additionally, the PATH Study collects biospecimens from consenting adults aged 18 years and older and measures biomarkers of exposure and potential harm related to tobacco use.Conclusions The cumulative, population-based data generated over time by the PATH Study will contribute to the evidence base to inform FDA's regulatory mission under the Family Smoking Prevention and Tobacco Control Act and efforts to reduce the Nation's burden of tobacco-related death and disease.